Tumor infiltrating immune cells in gliomas and meningiomas

Brain, Behavior, and Immunity

Volumn 53, Issue , 2016, Pages 1-15

  Domingues, Patrícia ^a,b   González Tablas, María ^b   Otero, Álvaro ^c   Pascual, Daniel ^c   Miranda, David ^c   Ruiz, Laura ^c   Sousa, Pablo ^c   Ciudad, Juana ^b   Gonçalves, Jesús María ^c   Lopes, María Celeste ^a   Orfao, Alberto ^b   Tabernero, María Dolores ^b,c  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b CSIC   (Spain)

^c HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Brain tumors; Glioma; Immune cells; Immune infiltration; Lymphoid cells; Meningioma; Microenvironment; Multiparameter flow cytometry; Myeloid cells

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ALPHA INTERFERON; ALPHA2B INTERFERON; BEVACIZUMAB; CETUXIMAB; CINTREDEKIN BESUDOTOX; CYTOKINE; DENDRITIC CELL VACCINE; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2; INTERLEUKIN 4 CYTOTOXIN; IPILIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 806; NIMOTUZUMAB; PANITUMUMAB; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; RAMUCIRUMAB; RINDOPEPIMUT; TRABEDERSEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPOSITION; CELL INFILTRATION; CEREBROSPINAL FLUID; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GLIOMA; HUMAN; IMMUNOCOMPETENT CELL; MACROPHAGE; MENINGIOMA; MICROGLIA; MYELOID DERIVED SUPPRESSOR CELL; NATURAL KILLER CELL; NEUTROPHIL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; BRAIN TUMOR; FLOW CYTOMETRY; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PATHOLOGY;

ANIMALS; B-LYMPHOCYTES; BRAIN NEOPLASMS; FLOW CYTOMETRY; GLIOMA; HUMANS; LYMPHOCYTES; MACROPHAGES; MENINGEAL NEOPLASMS; MENINGIOMA; T-LYMPHOCYTES, REGULATORY;

EID: 84959528760     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.07.019     Document Type: Review

References (143)

1. Abbott N.J., Patabendige A.A., Dolman D.E., Yusof S.R., Begley D.J. Structure and function of the blood-brain barrier. Neurobiol. Dis. 2010, 37:13-25.
2. Alizadeh D., Zhang L., Brown C.E., et al. Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin. Cancer Res. 2010, 16:3399-3408.
3. Anguille S., Smits E.L., Lion E., van Tendeloo V.F., Berneman Z.N. Clinical use of dendritic cells for cancer therapy. Lancet 2014, 15:e257-e267.
4. Asai J., Suzuki R., Fujimoto T., et al. Fluorescence automatic cell sorter and immunohistochemical investigation of CD68-positive cells in meningioma. Clin. Neurol. Neurosurg. 1999, 101:229-234.
5. Audoy-Remus J., Richard J.F., Soulet D., et al. Rod-Shaped monocytes patrol the brain vasculature and give rise to perivascular macrophages under the influence of proinflammatory cytokines and angiopoietin-2. J. Neurosci. 2008, 28:10187-10199.
6. Backer-Grondahl T., Moen B.H., Arnli M.B., Torseth K., Torp S.H. Immunohistochemical characterization of brain-invasive meningiomas. Int. J. Clin. Exp. Pathol. 2014, 7:7206-7219.
7. Badie B., Schartner J.M. Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery 2000, 46:957-961. (discussion 61-2).
8. Badie B., Schartner J., Prabakaran S., Paul J., Vorpahl J. Expression of Fas ligand by microglia: possible role in glioma immune evasion. J. Neuroimmunol. 2001, 120:19-24.
9. Barros M.H., Hauck F., Dreyer J.H., Kempkes B., Niedobitek G. Macrophage polarisation: an immunohistochemical approach for identifying M1 and M2 macrophages. PloS One 2013, 8:e80908.
10. Bethke K., Staib F., Distler M., et al. Different efficiency of heat shock proteins (HSP) to activate human monocytes and dendritic cells: superiority of HSP60. J. Immunol. 2002, 169:6141-6148.
11. + Treg. Eur. J. Immunol. 2009, 39:1323-1333.
12. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010, 11:889-896.
13. Bloch O., Crane C.A., Kaur R., et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin. Cancer Res. 2013.
14. Braun B., Lange M., Oeckler R., Mueller M.M. Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. J. Neuro Oncol. 2004, 68:131-140.
15. Buckner J.C., Schomberg P.J., McGinnis W.L., et al. A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer 2001, 92:420-433.
16. Bunevicius A., Deltuva V.P., Deltuviene D., Tamasauskas A., Bunevicius R. Brain lesions manifesting as psychiatric disorders: eight cases. CNS Spectr. 2008, 13:950-958.
17. Candolfi M., Curtin J.F., Yagiz K., et al. B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 2011, 13:947-960.
18. Capuron L., Ravaud A., Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J. Clin. Oncol. 2000, 18:2143-2151.
19. Capuron L., Ravaud A., Neveu P.J., et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
20. Castriconi R., Daga A., Dondero A., et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 2009, 182:3530-3539.
21. Chang Q., Hedley D. Emerging applications of flow cytometry in solid tumor biology. Methods 2012, 57:359-367.
22. Cheema F.A., Badr A., Iqbal J. Glioblastoma multiforme presenting as treatment-resistant depression. J. Neuropsychiatry Clin. Neurosci. 2010, 22(123):E26.
23. + T cells in glioma patients. Neuro Oncol. 2010, 12:7-13.
24. D'Agostino P.M., Gottfried-Blackmore A., Anandasabapathy N., Bulloch K. Brain dendritic cells: biology and pathology. Acta Neuropathol. 2012, 124:599-614.
25. Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann. N. Y. Acad. Sci. 2001, 933:222-234.
26. Dantzer R., O'Connor J.C., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
27. Davies L.C., Jenkins S.J., Allen J.E., Taylor P.R. Tissue-resident macrophages. Nat. Immunol. 2013, 14:986-995.
28. de Graaf M.T., de Jongste A.H., Kraan J., et al. Flow cytometric characterization of cerebrospinal fluid cells. Cytometry B Clin. Cytom. 2011, 80:271-281.
29. Debinski W., Obiri N.I., Powers S.K., Pastan I., Puri R.K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res. 1995, 1:1253-1258.
30. Derecki N.C., Katzmarski N., Kipnis J., Meyer-Luehmann M. Microglia as a critical player in both developmental and late-life CNS pathologies. Acta Neuropathol. 2014, 128:333-345.
31. Dinarello C.A. Blocking IL-1 in systemic inflammation. J. Exp. Med. 2005, 201:1355-1359.
32. Domingues P.H., Teodosio C., Ortiz J., et al. Immunophenotypic identification and characterization of tumor cells and infiltrating cell populations in meningiomas. Am. J. Pathol. 2012, 181:1749-1761.
33. Domingues P.H., Teodosio C., Otero A., et al. The protein expression profile of meningioma cells is associated with distinct cytogenetic tumour subgroups. Neuropathol. Appl. Neurobiol. 2014.
34. Domingues P.H., Sousa P., Otero A., et al. Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype. Neuro Oncol. 2014, 16:735-747.
35. Dunn G.P., Dunn I.F., Curry W.T. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human glioma. Cancer Immun. 2007, 7:12.
36. Edin S., Wikberg M.L., Dahlin A.M., et al. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 2012, 7:e47045.
37. + regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol. 2006, 8:234-243.
38. + T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J. Neuro Oncol. 2007, 83:145-152.
39. Epari S., Sharma M.C., Sarkar C., et al. Chordoid meningioma, an uncommon variant of meningioma: a clinicopathologic study of 12 cases. J. Neuro Oncol. 2006, 78:263-269.
40. Fang L., Lowther D.E., Meizlish M.L., et al. The immune cell infiltrate populating meningiomas is composed of mature, antigen-experienced T and B cells. Neuro Oncol. 2013, 15:1479-1490.
41. Fathi A.R., Roelcke U. Meningioma. Curr. Neurol. Neurosci. Rep. 2013, 13:337.
42. Ford E., Catt S., Chalmers A., Fallowfield L. Systematic review of supportive care needs in patients with primary malignant brain tumors. Neuro Oncol. 2012, 14:392-404.
43. Fridman W.H., Pages F., Sautes-Fridman C., Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 2012, 12:298-306.
44. Gabrusiewicz K., Ellert-Miklaszewska A., Lipko M., et al. Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One 2011, 6:e23902.
45. Galarneau H., Villeneuve J., Gowing G., Julien J.P., Vallieres L. Increased glioma growth in mice depleted of macrophages. Cancer Res. 2007, 67:8874-8881.
46. Gehring K., Sitskoorn M.M., Gundy C.M., et al. Cognitive rehabilitation in patients with gliomas: a randomized, controlled trial. J. Clin. Oncol. 2009, 27:3712-3722.
47. +T regulatory and dendritic cells in patients with gliomas. J. Neuroimmunol. 2013, 264:84-90.
48. Gregg N., Arber A., Ashkan K., et al. Neurobehavioural changes in patients following brain tumour: patients and relatives perspective. Support Care Cancer 2014, 22:2965-2972.
49. Grund S., Schittenhelm J., Roser F., et al. The microglial/macrophagic response at the tumour-brain border of invasive meningiomas. Neuropathol. Appl. Neurobiol. 2009, 35:82-88.
50. Guillemin G.J., Brew B.J. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J. Leukoc. Biol. 2004, 75:388-397.
51. Hagemann T., Lawrence T., McNeish I., et al. "Re-educating" tumor-associated macrophages by targeting NF-kappaB. J. Exp. Med. 2008, 205:1261-1268.
52. Hamilton A., Sibson N.R. Role of the systemic immune system in brain metastasis. Mol. Cell Neurosci. 2013, 53:42-51.
53. Hao N.B., Lu M.H., Fan Y.H., et al. Macrophages in tumor microenvironments and the progression of tumors. Clin. Dev. Immunol. 2012, 2012:948098.
54. Hau P., Jachimczak P., Schlingensiepen R., et al. Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007, 17:201-212.
55. Hayes R.L., Arbit E., Odaimi M., et al. Adoptive cellular immunotherapy for the treatment of malignant gliomas. Crit. Rev. Oncol./Hematol. 2001, 39:31-42.
56. + regulatory T cells in human gliomas. Clin. Cancer Res. 2008, 14:5166-5172.
57. Hjelmeland M.D., Hjelmeland A.B., Sathornsumetee S., et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. Mol. Cancer Ther. 2004, 3:737-745.
58. Hoepner S., Loh J.M., Riccadonna C., et al. Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumours. PloS One 2013, 8:e63933.
59. Huang Y., Hoffman C., Rajappa P., et al. Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Res. 2014, 74:1011-1021.
60. Hussain S.F., Yang D., Suki D., et al. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro Oncol. 2006, 8:261-279.
61. Hussain S.F., Yang D., Suki D., Grimm E., Heimberger A.B. Innate immune functions of microglia isolated from human glioma patients. J. Transl. Med. 2006, 4:15.
62. Hussain S.F., Kong L.Y., Jordan J., et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007, 67:9630-9636.
63. Italiani P., Boraschi D. From monocytes to M1/M2 macrophages: phenotypical vs. functional differentiation. Front. Immunol. 2014, 5:514.
64. Jacobs J.F., Idema A.J., Bol K.F., et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009, 11:394-402.
65. Jarboe J.S., Johnson K.R., Choi Y., Lonser R.R., Park J.K. Expression of interleukin-13 receptor alpha2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res. 2007, 67:7983-7986.
66. Johns T.G., Luwor R.B., Murone C., et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15871-15876.
67. Johnson T.S., Munn D.H., Maria B.L. Modulation of tumor tolerance in primary central nervous system malignancies. Clin. Dev. Immunol. 2012, 2012:937253.
68. Kakar S., Puangsuvan N., Stevens J.M., et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol. Diagn. 2000, 5:199-207.
69. Kettenmann H., Hanisch U.K., Noda M., Verkhratsky A. Physiology of microglia. Physiol. Rev. 2011, 91:461-553.
70. Khaled Y.S., Ammori B.J., Elkord E. Myeloid-derived suppressor cells in cancer: recent progress and prospects. Immunol. Cell Biol. 2013, 91:493-502.
71. Kim Y.H., Jung T.Y., Jung S., et al. Tumour-infiltrating T-cell subpopulations in glioblastomas. Br. J. Neurosurg. 2012, 26:21-27.
72. + tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J. Neuroimmunol. 2013, 264:71-83.
73. Kmiecik J., Zimmer J., Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J. Neuro Oncol. 2014, 116:1-9.
74. Kohanbash G., Okada H. Myeloid-derived suppressor cells (MDSCs) in gliomas and glioma-development. Immunol. Invest. 2012, 41:658-679.
75. Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008, 216:15-24.
76. Kowarik M.C., Grummel V., Wemlinger S., et al. Immune cell subtyping in the cerebrospinal fluid of patients with neurological diseases. J. Neurol. 2014, 261:130-143.
77. Kumar R., Kamdar D., Madden L., et al. Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol. Rep. 2006, 15:1513-1516.
78. Kunwar S., Prados M.D., Chang S.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 2007, 25:837-844.
79. Kunwar S., Chang S., Westphal M., et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010, 12:871-881.
80. Legres L.G., Janin A., Masselon C., Bertheau P. Beyond laser microdissection technology: follow the yellow brick road for cancer research. Am. J. Cancer Res. 2014, 4:1-28.
81. Lohr J., Ratliff T., Huppertz A., et al. Effector T-cell infiltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin. Cancer Res. 2011, 17:4296-4308.
82. Lossinsky A.S., Shivers R.R. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Histol. Histopathol. 2004, 19:535-564.
83. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
84. Louveau A., Smirnov I., Keyes T.J., et al. Structural and functional features of central nervous system lymphatic vessels. Nature 2015.
85. Maes W., Verschuere T., Van Hoylandt A., Boon L., Van Gool S. Depletion of regulatory T cells in a mouse experimental glioma model through anti-CD25 treatment results in the infiltration of non-immunosuppressive myeloid cells in the brain. Clin. Dev. Immunol. 2013, 2013:952469.
86. + lymphocytes predict clinical outcome in breast cancer. J. Clin. Oncol. 2011, 29:1949-1955.
87. Mantovani A., Sica A., Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-346.
88. Mantovani A., Romero P., Palucka A.K., Marincola F.M. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783.
89. Matos L.L., Trufelli D.C., de Matos M.G., da Silva Pinhal M.A. Immunohistochemistry as an important tool in biomarkers detection and clinical practice. Biomarker Insights 2010, 5:9-20.
90. Mineo J.F., Bordron A., Quintin-Roue I., et al. Recombinant humanised anti-HER2/neu antibody (Herceptin) induces cellular death of glioblastomas. Br. J. Cancer 2004, 91:1195-1199.
91. Muraille E., Leo O., Moser M. TH1/TH2 paradigm extended: macrophage polarization as an unappreciated pathogen-driven escape mechanism?. Front. Immunol. 2014, 5:603.
92. + B cells: the other tumor-infiltrating lymphocytes. J. Immunol. 2010, 185:4977-4982.
93. Okada M., Saio M., Kito Y., et al. Tumor-associated macrophage/microglia infiltration in human gliomas is correlated with MCP-3, but not MCP-1. Int. J. Oncol. 2009, 34:1621-1627.
94. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J. Clin. Oncol. 2011, 29:330-336.
95. *0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin. Cancer Res. 2002, 8:2851-2855.
96. Olson J.J., McKenzie E., Skurski-Martin M., et al. Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme. J. Neuro Oncol. 2008, 90:293-299.
97. Ousman S.S., Kubes P. Immune surveillance in the central nervous system. Nat. Neurosci. 2012, 15:1096-1101.
98. Pages F., Kirilovsky A., Mlecnik B., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009, 27:5944-5951.
99. Parney I.F., Waldron J.S., Parsa A.T. Flow cytometry and in vitro analysis of human glioma-associated macrophages. Laboratory investigation. J. Neurosurg. 2009, 110:572-582.
100. Patel D., Lahiji A., Patel S., et al. Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface. Anticancer Res. 2007, 27:3355-3366.
101. Perera R.M., Narita Y., Furnari F.B., et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. 2005, 11:6390-6399.
102. Predina J., Eruslanov E., Judy B., et al. Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:E415-E424.
103. Prinz M., Tay T.L., Wolf Y., Jung S. Microglia: unique and common features with other tissue macrophages. Acta Neuropathol. 2014, 128:319-331.
104. Pyonteck S.M., Akkari L., Schuhmacher A.J., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
105. Quail D.F., Joyce J.A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013, 19:1423-1437.
106. Quijano S., Lopez A., Manuel Sancho J., et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J. Clin. Oncol. 2009, 27:1462-1469.
107. Rand R.W., Kreitman R.J., Patronas N., et al. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin. Cancer Res. 2000, 6:2157-2165.
108. Raychaudhuri B., Rayman P., Ireland J., et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011, 13:591-599.
109. Rodrigues J.C., Gonzalez G.C., Zhang L., et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010, 12:351-365.
110. Roessler K., Dietrich W., Kitz K. Expression of BCL-2 oncoprotein on tumor cells and tumor-infiltrating lymphocytes (TIL) in meningiomas. Neurosurg. Rev. 1999, 22:205-209.
111. Romo-Gonzalez T., Chavarria A., Perez H.J. Central nervous system: a modified immune surveillance circuit?. Brain Behav. Immun. 2012, 26:823-829.
112. Sampson J.H., Crotty L.E., Lee S., et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7503-7508.
113. Sampson J.H., Heimberger A.B., Archer G.E., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2010, 28:4722-4729.
114. Schartner J.M., Hagar A.R., Van Handel M., et al. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia 2005, 51:279-285.
115. Schuster J., Lai R.K., Recht L.D., et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015, 17:854-861.
116. Scott A.M., Lee F.T., Tebbutt N., et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:4071-4076.
117. Serrats J., Schiltz J.C., Garcia-Bueno B., et al. Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron 2010, 65:94-106.
118. Sharda D.R., Yu S., Ray M., et al. Regulation of macrophage arginase expression and tumor growth by the Ron receptor tyrosine kinase. J. Immunol. 2011, 187:2181-2192.
119. Shiao S.L., Ganesan A.P., Rugo H.S., Coussens L.M. Immune microenvironments in solid tumors: new targets for therapy. Genes Dev. 2011, 25:2559-2572.
120. Shimato S., Maier L.M., Maier R., et al. Profound tumor-specific Th2 bias in patients with malignant glioma. BMC Cancer 2012, 12:561.
121. Sielska M., Przanowski P., Wylot B., et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response. J. Pathol. 2013, 230:310-321.
122. Strik H.M., Stoll M., Meyermann R. Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res. 2004, 24:37-42.
123. Sun W., Depping R., Jelkmann W. Interleukin-1beta promotes hypoxia-induced apoptosis of glioblastoma cells by inhibiting hypoxia-inducible factor-1 mediated adrenomedullin production. Cell Death Dis. 2014, 5:e1020.
124. Szulzewsky F., Pelz A., Feng X., et al. Glioma-associated microglia/macrophages display an expression profile different from m1 and m2 polarization and highly express gpnmb and spp1. PloS One 2015, 10:e0116644.
125. Taphoorn M.J., Klein M. Cognitive deficits in adult patients with brain tumours. Lancet Neurol. 2004, 3:159-168.
126. Tyrinova T.V., Leplina O.Y., Mishinov S.V., et al. Cytotoxic activity of ex-vivo generated IFNalpha-induced monocyte-derived dendritic cells in brain glioma patients. Cell Immunol. 2013, 284:146-153.
127. Umemura N., Saio M., Suwa T., et al. Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 2008, 83:1136-1144.
128. van Dongen J.J., Lhermitte L., Bottcher S., et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 2012, 26:1908-1975.
129. Wainwright D.A., Nigam P., Thaci B., Dey M., Lesniak M.S. Recent developments on immunotherapy for brain cancer. Expert Opin. Emerg. Drugs 2012, 17:181-202.
130. Wainwright D.A., Chang A.L., Dey M., et al. Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin. Cancer Res. 2014, 20:5290-5301.
131. Wang X., Li C., Chen Y., et al. Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem. Biophys. Res. Commun. 2008, 371:283-288.
132. + T cell activation and expansion within human glioblastoma. J. Immunol. 2008, 180:7673-7680.
133. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
134. Wu G., Yang W., Barth R.F., et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 2007, 13:1260-1268.
135. Wynn T.A., Chawla A., Pollard J.W. Macrophage biology in development, homeostasis and disease. Nature 2013, 496:445-455.
136. + T cells to mediate neuroprotection. Brain Behav. Immun. 2011, 25:820-829.
137. Yang W., Barth R.F., Wu G., et al. Molecular targeting and treatment of EGFRvIII-positive gliomas using boronated monoclonal antibody L8A4. Clin. Cancer Res. 2006, 12:3792-3802.
138. Yang I., Han S.J., Kaur G., Crane C., Parsa A.T. The role of microglia in central nervous system immunity and glioma immunology. J. Clin. Neurosci. 2010, 17:6-10.
139. Yang I., Han S.J., Sughrue M.E., Tihan T., Parsa A.T. Immune cell infiltrate differences in pilocytic astrocytoma and glioblastoma: evidence of distinct immunological microenvironments that reflect tumor biology. J. Neurosurg. 2011, 115:505-511.
140. Yao S., Zhu Y., Zhu G., et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011, 34:729-740.
141. Yu J.S., Lee P.K., Ehtesham M., et al. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J. Neuro Oncol. 2003, 64:55-61.
142. Yuile P., Dent O., Cook R., Biggs M., Little N. Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables. J. Clin. Neurosci. 2006, 13:747-751.
143. Zisakis A., Piperi C., Themistocleous M.S., et al. Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine 2007, 39:99-105.